FDA says no to Xarelto for ACS; Puma bags $138M;

@FierceBiotech: Follow the money: Our John Carroll talks money, geography and biotech. Editor's Corner | Follow @FierceBiotech

@JohnCFierce: Rare-disease powerhouse Alexion grabs an option on muscular dystrophy buyout. More | Follow @JohnCFierce

@DamianFierce: Astellas finally bails on $AVEO, giving up on the thrice-failed tivozanib. Story | Follow @DamianFierce

@EmilyMFierce: BioLineRx shows effectiveness of leukemia drug in preclinical study. Article via FierceBiotech Research | Follow @EmilyMFierce

> The FDA has denied Johnson & Johnson's ($JNJ) efforts to get Xarelto indicated for patients with acute coronary syndrome. Story

> Puma Biotechnology ($PBYI) raised about $138 million in a stock offering. More

> Audeo Oncology has withdrawn its pitch to go public in a $49 million IPO. News

Medical Device News

@FierceMedDev: Israel's Lumenis is plowing ahead with a planned $100M IPO--device market wariness be damned. Story | Follow @FierceMedDev

@MarkHFierce: Philips scored a strategically smart remote patent monitoring deal with Boston's Partners Healthcare. Article | Follow @MarkHFierce

@MichaelGFierce: This week's Chutes&Ladders: Ex-Gilead Irish operations leader joins Alexion to expand in Dublin, Athlone. Report | Follow @MichaelGFierce

@EmilyWFierce: No love for Aveo and Astellas: Companies 'breakup,' end pact to develop cancer drug. Article | Follow @EmilyWFierce

> By winning New York Dx certification, Ariosa gains a valuable marketing tool. Item

> Medtronic unveils a new treatment for peripheral artery disease in Europe. Story

> Ahead of its acquisition by Smith & Nephew, ArthroCare shows its profit. News

Pharma News

@FiercePharma: Here's why a crowdfunded HIV vaccine project is drawing criticism from some scientists. More | Follow @FiercePharma

@TracyStaton: Gilead won't make hep C sales projections, but doesn't mind if you do. Provided they're huge. Piece | Follow @TracyStaton

@EricPFierce: CEO Bresch's moves in India give Mylan low-cost production tied to a high-value rep. Report | Follow @EricPFierce

@CarlyHFierce: Shire steers Vyvanse toward binge eating as earnings come up aces. Article | Follow @CarlyHFierce

> Doxycycline sales power Hikma, but the party may be ending. News

> No FDA love for Xarelto in ACS patients. Story

Suggested Articles

Californian RNA biotech Arrowhead will lose its COO and R&D head from next year but is hiring a new CMO and CSO to help steady its research exec team.

The biotech began testing the small molecule in a phase 3 trial of heavily pretreated small cell lung cancer patients late last year. 

Roche is spending up to $1.4 billion to snap up a scarring-focused biotech, nabbing an FDA breakthrough-tagged therapy in the process.